Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing ADG20 EUA submissions planned for prevention and treatment of COVID-19 in